RecruitingPhase 2NCT03243019

Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations

Evaluation of the Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations of Poor Prognosis

Sponsor

University Hospital, Lille

Enrollment

28 participants

Start Date

Jun 25, 2018

Study Type

INTERVENTIONAL

Conditions

Pediatric Lymphatic Malformation

Summary

To evaluate the efficacy of Rapamycin in extended cervicofacial lymphatic malformations in pediatric patients. Rapamycin is administered oral for a 6 month period. The success rate is determined by volume reduction superior to 1/5e of the initial volume measured by MRI, impact on QOL and reduction of bleeding in case of mucosal involvement.

Eligibility

Max Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called MRI, a biological treatment called Rapamycin dosage, and others for people with lymphatic malformation and pediatric. The study is currently recruiting participants at 2 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.